FRLN — Freeline Therapeutics Holdings Share Price
Last trade - 00:00- $28.24m
- -$1.21m
- 22
- 17
- 67
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | 0.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 45.4 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -149.95% | ||
| Return on Equity | -101.26% | ||
| Operating Margin | -7652.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 0.6 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Freeline Therapeutics Holdings plc is a clinical-stage biotechnology company. The Company is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from chronic debilitating diseases. It uses its rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. It is advancing FLT201, a differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Therapeutic AAV vectors consist of two main components: the capsid and the expression cassette (that contains the gene and the promoter). It has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- April 3rd, 2020
- Public Since
- August 7th, 2020
- No. of Shareholders
- 26
- No. of Employees
- 152
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 65,369,206
- Address
- Sycamore House, STEVENAGE, SG1 2BP
- Web
- https://www.freeline.life/
- Phone
- +44 1438906870
- Auditors
- Deloitte LLP
Latest News for FRLN
Upcoming Events for FRLN
Q4 2023 Freeline Therapeutics Holdings PLC Earnings Release
Q1 2024 Freeline Therapeutics Holdings PLC Earnings Release
Freeline Therapeutics Holdings PLC Annual Shareholders Meeting
Q2 2024 Freeline Therapeutics Holdings PLC Earnings Release
Similar to FRLN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 18:08 UTC, shares in Freeline Therapeutics Holdings are trading at $6.48. This share price information is delayed by 15 minutes.
Shares in Freeline Therapeutics Holdings last closed at $6.48 and the price had moved by -20% over the past 365 days. In terms of relative price strength the Freeline Therapeutics Holdings share price has underperformed the S&P500 Index by -34.81% over the past year.
The overall consensus recommendation for Freeline Therapeutics Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreFreeline Therapeutics Holdings does not currently pay a dividend.
Freeline Therapeutics Holdings does not currently pay a dividend.
Freeline Therapeutics Holdings does not currently pay a dividend.
To buy shares in Freeline Therapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.48, shares in Freeline Therapeutics Holdings had a market capitalisation of $28.24m.
Here are the trading details for Freeline Therapeutics Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: FRLN
Based on an overall assessment of its quality, value and momentum Freeline Therapeutics Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Freeline Therapeutics Holdings is $8.25. That is 27.31% above the last closing price of $6.48.
Analysts covering Freeline Therapeutics Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$0.64 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Freeline Therapeutics Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +29.45%.
As of the last closing price of $6.48, shares in Freeline Therapeutics Holdings were trading +41.48% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Freeline Therapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Freeline Therapeutics Holdings' directors